

Title (en)  
BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES

Title (de)  
BIOLOGISCH-WIRKSAME 1,3-BIS-AROMATISCHE-PROP-2-EN-1-ON, 1,3-BIS-AROMATISCHE-PROPAN-1-ON, AND 1,3-BIS-AROMATISCHE-PROP-2-YN-1-ON

Title (fr)  
1,3-BIS-AROMATIQUE-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIQUE-PROPANE-1-ONES ET 1,3-BIS-AROMATIQUE-PROP-2-YN-1-ONES A ACTION BIOLOGIQUE

Publication  
**EP 0996432 A2 20000503 (EN)**

Application  
**EP 98929241 A 19980626**

Priority  
• DK 9800283 W 19980626  
• DK 76297 A 19970626

Abstract (en)  
[origin: WO9900114A2] The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infections by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.

IPC 1-7  
**A61K 31/12; A61K 31/135; A61K 31/275; C07C 49/84; C07C 205/45; C07C 225/22; C07C 255/56**

IPC 8 full level  
**A61K 31/12** (2006.01); **A61K 31/136** (2006.01); **A61K 31/277** (2006.01); **C07C 45/00** (2006.01); **C07C 45/41** (2006.01); **C07C 45/45** (2006.01); **C07C 45/67** (2006.01); **C07C 45/74** (2006.01); **C07C 49/813** (2006.01); **C07C 49/84** (2006.01); **C07C 205/45** (2006.01); **C07C 217/22** (2006.01); **C07C 217/36** (2006.01); **C07C 225/16** (2006.01); **C07C 225/22** (2006.01); **C07C 233/33** (2006.01); **C07C 255/40** (2006.01)

CPC (source: EP)  
**A61K 31/12** (2013.01); **A61K 31/136** (2013.01); **A61K 31/277** (2013.01); **C07C 45/00** (2013.01); **C07C 45/41** (2013.01); **C07C 45/455** (2013.01); **C07C 45/67** (2013.01); **C07C 45/673** (2013.01); **C07C 45/74** (2013.01); **C07C 49/813** (2013.01); **C07C 49/84** (2013.01); **C07C 205/45** (2013.01); **C07C 217/22** (2013.01); **C07C 217/36** (2013.01); **C07C 225/16** (2013.01); **C07C 225/22** (2013.01); **C07C 233/33** (2013.01); **C07C 255/40** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)  
See references of WO 9900114A2

Designated contracting state (EPC)  
AT BE CH DE DK ES FI FR GB IT LI NL SE

DOCDB simple family (publication)  
**WO 9900114 A2 19990107; WO 9900114 A3 19990812; AU 7908098 A 19990119; EP 0996432 A2 20000503**

DOCDB simple family (application)  
**DK 9800283 W 19980626; AU 7908098 A 19980626; EP 98929241 A 19980626**